Oct-3/4 is a dose-dependent oncogenic fate determinant

Cancer Cell

Volumn 4, Issue 5, 2003, Pages 361-370

  Gidekel, Sharon ^a   Pizov, Galina ^b   Bergman, Yehudit ^a   Pikarsky, Eli ^b  

^a HEBREW UNIVERSITY   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR OCT 3/4; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CARCINOGENESIS; CARCINOGENICITY; CELL FATE; CELL ONCOGENE; CELL TRANSFORMATION; CONTROLLED STUDY; EMBRYO; EMBRYO CELL; GENE EXPRESSION; GERM CELL TUMOR; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SPERMATOGONIUM; STEM CELL; TUMOR REGRESSION;

ANIMALIA; MUS MUSCULUS;

EID: 0344063368     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(03)00270-8     Document Type: Article

References (58)

1. Abate-Shen C. Deregulated homeobox gene expression in cancer. cause or consequence? Nat. Rev. Cancer. 2:2002;777-785.
2. Ben-Shushan E., Pikarsky E., Klar A., Bergman Y. Extinction of Oct-3/4 gene expression in embryonal carcinoma x fibroblast somatic cell hybrids is accompanied by changes in the methylation status, chromatin structure, and transcriptional activity of the Oct-3/4 upstream region. Mol. Cell. Biol. 13:1993;891-901.
3. Ben-Shushan E., Thompson J.R., Gudas L.J., Bergman Y. Rex-1, a gene encoding a transcription factor expressed in the early embryo, is regulated via Oct-3/4 and Oct-6 binding to an octamer site and a novel protein, Rox-1, binding to an adjacent site. Mol. Cell. Biol. 18:1998;1866-1878.
4. Boiani M., Eckardt S., Scholer H.R., McLaughlin K.J. Oct4 distribution and level in mouse clones. consequences for pluripotency Genes Dev. 16:2002;1209-1219.
5. Brehm A., Ohbo K., Scholer H. The carboxy-terminal transactivation domain of Oct-4 acquires cell specificity through the POU domain. Mol. Cell. Biol. 17:1997;154-162.
6. Brehm A., Ovitt C.E., Scholer H.R. Oct-4. more than just a POUerful marker of the mammalian germline? Apmis. 106:1998;114-124. discussion 124-116.
7. Chaganti R.S., Houldsworth J. Genetics and biology of adult human male germ cell tumors. Cancer Res. 60:2000;1475-1482.
8. Chin L., Tam A., Pomerantz J., Wong M., Holash J., Bardeesy N., Shen Q., O'Hagan R., Pantginis J., Zhou H., et al. Essential role for oncogenic Ras in tumour maintenance. Nature. 400:1999;468-472.
9. Dahmane N., Sanchez P., Gitton Y., Palma V., Sun T., Beyna M., Weiner H., Ruiz i Altaba A. The Sonic Hedgehog-Gli pathway regulates dorsal brain growth and tumorigenesis. Development. 128:2001;5201-5212.
10. Damjanov I. Human yolk sac carcinoma antigens-a step beyond alpha-fetoprotein. Lab. Invest. 57:1987;347-349.
11. D'Cruz C.M., Gunther E.J., Boxer R.B., Hartman J.L., Sintasath L., Moody S.E., Cox J.D., Ha S.I., Belka G.K., Golant A., et al. c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nat. Med. 7:2001;235-239.
12. Donovan P.J. High Oct-ane fuel powers the stem cell. Nat. Genet. 29:2001;246-247.
13. Ewald D., Li M., Efrat S., Auer G., Wall R.J., Furth P.A., Hennighausen L. Time-sensitive reversal of hyperplasia in transgenic mice expressing SV40 T antigen. Science. 273:1996;1384-1386.
14. Felsher D.W., Bishop J.M. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol. Cell. 4:1999;199-207. a.
15. Felsher D.W., Bishop J.M. Transient excess of MYC activity can elicit genomic instability and tumorigenesis. Proc. Natl. Acad. Sci. USA. 96:1999;3940-3944. b.
16. Fisher G.H., Wellen S.L., Klimstra D., Lenczowski J.M., Tichelaar J.W., Lizak M.J., Whitsett J.A., Koretsky A., Varmus H.E. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev. 15:2001;3249-3262.
17. Gidekel S., Bergman Y. A unique developmental pattern of Oct-3/4 DNA methylation is controlled by a cis-demodification element. J. Biol. Chem. 277:2002;34521-34530.
18. Grachtchouk M., Mo R., Yu S., Zhang X., Sasaki H., Hui C.C., Dlugosz A.A. Basal cell carcinomas in mice overexpressing Gli2 in skin. Nat. Genet. 24:2000;216-217.
19. Hammel I., Lagunoff D., Kruger P.G. Recovery of rat mast cells after secretion. a morphometric study Exp. Cell Res. 184:1989;518-523.
20. Hellerstedt B.A., Pienta K.J. Testicular cancer. Curr. Opin. Oncol. 14:2002;260-264.
21. Huettner C.S., Zhang P., Van Etten R.A., Tenen D.G. Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat. Genet. 24:2000;57-60.
22. Jain M., Arvanitis C., Chu K., Dewey W., Leonhardt E., Trinh M., Sundberg C.D., Bishop J.M., Felsher D.W. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science. 297:2002;102-104.
23. Karlsson A., Giuriato S., Tang F., Fung-Weier J., Levan G., Felsher D.W. Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations. Blood. 101:2003;2797-2803.
24. Looijenga L.H., Oosterhuis J.W. Pathogenesis of testicular germ cell tumours. Rev. Reprod. 4:1999;90-100.
25. Looijenga L.H., Stoop H., De Leeuw H.P., De Gouveia Brazao C.A., Gillis A.J., Van Roozendaal K.E., Van Zoelen E.J., Weber R.F., Wolffenbuttel K.P., Van Dekken H., et al. POU5F1 (OCT3/4) identifies cells with pluripotent potential in human germ cell tumors. Cancer Res. 63:2003;2244-2250.
26. Maulbecker C.C., Gruss P. The oncogenic potential of deregulated homeobox genes. Cell Growth Differ. 4:1993;431-441.
27. Nichols J., Zevnik B., Anastassiadis K., Niwa H., Klewe-Nebenius D., Chambers I., Scholer H., Smith A. Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4. Cell. 95:1998;379-391.
28. Nilsson M., Unden A.B., Krause D., Malmqwist U., Raza K., Zaphiropoulos P.G., Toftgard R. Induction of basal cell carcinomas and trichoepitheliomas in mice overexpressing GLI-1. Proc. Natl. Acad. Sci. USA. 97:2000;3438-3443.
29. Niwa H., Miyazaki J., Smith A.G. Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. Nat. Genet. 24:2000;372-376.
30. Norris H.J., Zirkin H.J., Benson W.L. Immature (malignant) teratoma of the ovary. a clinical and pathologic study of 58 cases Cancer. 37:1976;2359-2372.
31. Okamoto K., Okazawa H., Okuda A., Sakai M., Muramatsu M., Hamada H. A novel octamer binding transcription factor is differentially expressed in mouse embryonic cells. Cell. 60:1990;461-472.
32. Oliver R.T. Germ cell cancer. Curr. Opin. Oncol. 11:1999;236-241.
33. Palmieri S.L., Peter W., Hess H., Scholer H.R. Oct-4 transcription factor is differentially expressed in the mouse embryo during establishment of the first two extraembryonic cell lineages involved in implantation. Dev. Biol. 166:1994;259-267.
34. Palumbo C., van Roozendaal K., Gillis A.J., van Gurp R.H., de Munnik H., Oosterhuis J.W., van Zoelen E.J., Looijenga L.H. Expression of the PDGF alpha-receptor 1.5 kb transcript, OCT-4, and c-KIT in human normal and malignant tissues. Implications for the early diagnosis of testicular germ cell tumours and for our understanding of regulatory mechanisms. J. Pathol. 196:2002;467-477.
35. Pesce M., Scholer H.R. Oct-4. gatekeeper in the beginnings of mammalian development Stem Cells. 19:2001;271-278.
36. Pesce M., Wang X., Wolgemuth D.J., Scholer H. Differential expression of the Oct-4 transcription factor during mouse germ cell differentiation. Mech. Dev. 71:1998;89-98.
37. Polakis P. Wnt signaling and cancer. Genes Dev. 14:2000;1837-1851.
38. Qin X.F., Luo Y., Suh H., Wayne J., Misulovin Z., Roeder R.G., Nussenzweig M.C. Transformation by homeobox genes can be mediated by selective transcriptional repression. EMBO J. 13:1994;5967-5976.
39. Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature. 414:2001;105-111.
40. Rosner M.H., Vigano M.A., Ozato K., Timmons P.M., Poirier F., Rigby P.W., Staudt L.M. A POU-domain transcription factor in early stem cells and germ cells of the mammalian embryo. Nature. 345:1990;686-692.
41. Ryan A.K., Rosenfeld M.G. POU domain family values. flexibility, partnerships, and developmental codes Genes Dev. 11:1997;1207-1225.
42. Scholer H.R., Balling R., Hatzopoulos A.K., Suzuki N., Gruss P. Octamer binding proteins confer transcriptional activity in early mouse embryogenesis. EMBO J. 8:1989;2551-2557.
43. Scholer H.R., Dressler G.R., Balling R., Rohdewohld H., Gruss P. Oct-4. a germline-specific transcription factor mapping to the mouse t-complex EMBO J. 9:1990;2185-2195.
44. Soubeyran P., Haglund K., Garcia S., Barth B.U., Iovanna J., Dikic I. Homeobox gene Cdx1 regulates Ras, Rho and PI3 kinase pathways leading to transformation and tumorigenesis of intestinal epithelial cells. Oncogene. 20:2001;4180-4187.
45. Strohmeyer T., Peter S., Hartmann M., Munemitsu S., Ackermann R., Ullrich A., Slamon D.J. Expression of the hst-1 and c-kit protooncogenes in human testicular germ cell tumors. Cancer Res. 51:1991;1811-1816.
46. Stuart E.T., Yokota Y., Gruss P. PAX and HOX in neoplasia. Adv. Genet. 33:1995;255-274.
47. Suzuki K., Tokue A., Kamiakito T., Kuriki K., Saito K., Tanaka A. Predominant expression of fibroblast growth factor (FGF) 8, FGF4, and FGF receptor 1 in nonseminomatous and highly proliferative components of testicular germ cell tumors. Virchows Arch. 439:2001;616-621.
48. Taipale J., Beachy P.A. The Hedgehog and Wnt signalling pathways in cancer. Nature. 411:2001;349-354.
49. Ulbright T.M. Germ cell neoplasms of the testis. Am. J. Surg. Pathol. 17:1993;1075-1091.
50. van de Wetering M., Sancho E., Verweij C., de Lau W., Oving I., Hurlstone A., van der Horn K., Batlle E., Coudreuse D., Haramis A.P., et al. The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell. 111:2002;241-250.
51. Verrijzer C.P., Van der Vliet P.C. POU domain transcription factors. Biochim. Biophys. Acta. 1173:1993;1-21.
52. Vigano M.A., Staudt L.M. Transcriptional activation by Oct-3. evidence for a specific role of the POU-specific domain in mediating functional interaction with Oct-1 Nucleic Acids Res. 24:1996;2112-2118.
53. Wilder P.J., Kelly D., Brigman K., Peterson C.L., Nowling T., Gao Q.S., McComb R.D., Capecchi M.R., Rizzino A. Inactivation of the FGF-4 gene in embryonic stem cells alters the growth and/or the survival of their early differentiated progeny. Dev. Biol. 192:1997;614-629.
54. Yamamoto H., Ochiya T., Tamamushi S., Toriyama-Baba H., Takahama Y., Hirai K., Sasaki H., Sakamoto H., Saito I., Iwamoto T., et al. HST-1/FGF-4 gene activation induces spermatogenesis and prevents adriamycin-induced testicular toxicity. Oncogene. 21:2002;899-908.
55. Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology. 61(Suppl. 2):2001;1-13.
56. Yeom Y.I., Fuhrmann G., Ovitt C.E., Brehm A., Ohbo K., Gross M., Hubner K., Scholer H.R. Germline regulatory element of Oct-4 specific for the totipotent cycle of embryonal cells. Development. 122:1996;881-894.
57. Yoshida T., Tsutsumi M., Sakamoto H., Miyagawa K., Teshima S., Sugimura T., Terada M. Expression of the HST1 oncogene in human germ cell tumors. Biochem. Biophys. Res. Commun. 155:1988;1324-1329.
58. Zalel Y., Piura B., Elchalal U., Czernobilsky B., Antebi S., Dgani R. Diagnosis and management of malignant germ cell ovarian tumors in young females. Int. J. Gynaecol. Obstet. 55:1996;1-10.